Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

T. Blaettler · SciRah

Researcher profile · Semantic Scholar

T. Blaettler

Share profile

T. Blaettler — researcher profile on SciRah

h-index: 12
Works: 26
Citations: 653

Most-cited papers

Bitopertin in Negative Symptoms of Schizophrenia-Results From the Phase III FlashLyte and DayLyte Studies.
D. Bugarski-Kirola, T. Blaettler, C. Arango, W. Fleischhacker +10 more
2017Biological Psychiatry136 citations
Semantic Scholar
Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial.
E. Bertini, E. Dessaud, E. Mercuri, F. Muntoni +35 more
2017Lancet Neurology89 citations Open access
Semantic Scholar
Efficacy and safety of arimoclomol in Niemann‐Pick disease type C: Results from a double‐blind, randomised, placebo‐controlled, multinational phase 2/3 trial of a novel treatment
E. Mengel, M. Patterson, R. D. Da Riol, M. del Toro +19 more
2021Journal of Inherited Metabolic Disease78 citations Open access
Semantic Scholar
Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial p
D. Bugarski-Kirola, N. Iwata, S. Sameljak, Carol Reid +5 more
2016Lancet psychiatry65 citations
Semantic Scholar
Carboxy-terminated oligo(ethylene glycol)-alkane phosphate: synthesis and self-assembly on titanium oxide surfaces.
Mandy Gnauck, E. Jaehne, T. Blaettler, S. Tosatti +2 more
2007Langmuir57 citations
Semantic Scholar
Reliability, validity and ability to detect change of the PANSS negative symptom factor score in outpatients with schizophrenia on select antipsychotics and with prominent negative or disorganized thought symptoms.
Chris J. Edgar, T. Blaettler, D. Bugarski-Kirola, S. le Scouiller +2 more
2014Psychiatry Research37 citations
Semantic Scholar
Defining therapeutic benefit for people with schizophrenia: focus on negative symptoms.
N. Schooler, R. Buchanan, T. Laughren, S. Leucht +10 more
2015Schizophrenia Research34 citations
Semantic Scholar
A case-control study of sporadic Creutzfeldt-Jakob disease in Switzerland: analysis of potential risk factors with regard to an increased CJD incidence in the years 2001–2004
J. Ruegger, K. Stoeck, L. Amsler, T. Blaettler +5 more
2009BMC Public Health33 citations Open access
Semantic Scholar
AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation
D. Feuerbach, N. Pezous, M. Weiss, K. Shakeri-Nejad +11 more
2015British Journal of Pharmacology30 citations Open access
Semantic Scholar
Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial.
P. Machado, Michael P. McDermott, T. Blaettler, Claus Sundgreen +20 more
2023Lancet Neurology28 citations Open access
Semantic Scholar
Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
M. Benatar, T. Hansen, Dror Rom, M. A. Geist +33 more
2024Lancet Neurology20 citations Open access
Semantic Scholar
P2‐005: Evidence from Model‐Based Assessments of Compounds Tested in Completed Clinical Trials Indicates That The Amyloid Hypothesis Has Not Been Adequately Tested
T. Blaettler, Janice Smith, Jillian Smith, Robert Paul +8 more
201615 citations
Semantic Scholar
Efficacy and safety of adjunctive bitopertin (10 and 20mg) versus placebo in subjects with persistent predominant negative symptoms of schizophrenia treated with antipsychotics — Results from the Phase III FlashLyte Study
T. Blaettler, Dragana Bugarski-Kirola, W. Fleischhacker, R. Bressan +5 more
2014Schizophrenia Research12 citations
Semantic Scholar
EFFICACY AND SAFETY OF ADJUNCTIVE BITOPERTIN VERSUS PLACEBO IN SUBJECTS WITH PERSISTENT PREDOMINANT NEGATIVE SYMPTOMS OF SCHIZOPHRENIA TREATED WITH ANTIPSYCHOTICS – UPDATE FROM THE SEARCHLYTE PROGRAMME
D. Bugarski-Kirola, C. Arango, W. Fleischhacker, R. Bressan +6 more
201410 citations
Semantic Scholar
Safety, Tolerability, and EEG-Based Target Engagement of STP1 (PDE3,4 Inhibitor and NKCC1 Antagonist) in a Randomized Clinical Trial in a Subgroup of Patients with ASD
C. Erickson, Laura Pérez-Cano, E. Pedapati, Eric Painbeni +13 more
2024Biomedicines5 citations Open access
Semantic Scholar
O4‐05‐05: Free and Cued Selective Reminding Test as an Inclusion Criterion for Early Alzheimer's Disease Clinical Trial Populations
Janice Smith, Chris J. Edgar, R. Lasser, Shuguang Sun +2 more
20162 citations Open access
Semantic Scholar
ACh receptor partial agonist: pharmacological characterization and phase I
D. Feuerbach, N. Pezous, M. Weiss, K. Shakeri-Nejad +11 more
20152 citations
Semantic Scholar
The Early History of Arimoclomol for Inclusion Body Myositis
M. Dimachkie, P. Machado, C. Sundgreen, T. Blaettler +5 more
2021RRNMF Neuromuscular Journal1 citations Open access
Semantic Scholar
Design and rationale for a randomized, double-blind, placebo-controlled Phase 2/3 trial of oral arimoclomol in inclusion body myositis
P. Machado, R. Barohn, Michael P. McDermott, Claus Sundgreen +3 more
2024RRNMF Neuromuscular Journal0 citations Open access
Semantic Scholar
Persistent Effect of Arimoclomol in Patients with Niemann-Pick Disease Type C: 24-Month Results from an Open-Label Extension of a Pivotal Phase 2/3 Study
M. Patterson, E. Mengel, R. D. Da Riol, M. del Toro +19 more
2021Neuropediatrics0 citations
Semantic Scholar
A multinational, randomized, double-blind, placebo-controlled Phase 2 study to assess safety and efficacy of olesoxime in Type 2 or non-ambulatory Type 3 spinal muscular atrophy
Jeppe Buchbjerg, E. Bertini, Eric Dessaud, E. Mercuri +13 more
20170 citations
Semantic Scholar
AQW051, a novel, potent and selective nicotinic acetylcholine receptor α7 partial agonist: Pharmacological characterisation and Phase I evaluation in healthy subjects
D. Feuerbach, N. Pezous, M. Weiss, K. Shakeri-Nejad +11 more
20140 citations
Semantic Scholar
Validity and utility of the PANSS negative symptoms factor score as a clinical trial outcome
Chris J. Edgar, T. Blaettler, D. Bugarski-Kirola, S. le Scouiller +2 more
20140 citations
Semantic Scholar
Reliability and Validity of the PANSS Negative Symptom Factor Score in Outpatients with Schizophrenia Prescribed Select Antipsychotics and with Prominent Negative or Disorganized Thought Symptoms
Chris J. Edgar, T. Blaettler, D. Bugarski-Kirola, S. le Scouiller +1 more
20130 citations
Semantic Scholar
P3‐072: Assessing outcome measures for prodromal AD clinical trials: A retrospective analysis from the ADNI database
H. Feldman, T. Blaettler, Robert M. Berman, Jian Han +2 more
20090 citations
Semantic Scholar
Real Time Analyses of Myogenesis in Behaving Myoblasts
E. Thomasson, B. Staedler, T. Blaettler, J. Voeroes +1 more
20070 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

D. Bugarski-Kirola×7
Invite
D. Bugarski-Kirola — researcher profile on SciRah
George Garibaldi×7
Invite
George Garibaldi — researcher profile on SciRah
Carol Reid×5
Invite
Carol Reid — researcher profile on SciRah
S. Marder×5
Invite
S. Marder — researcher profile on SciRah

×5

Invite

Chris J. Edgar — researcher profile on SciRah

Invite

C. Arango — researcher profile on SciRah

W. Fleischhacker×3

Invite

W. Fleischhacker — researcher profile on SciRah

Invite

R. Bressan — researcher profile on SciRah

H. Nasrallah×3

Invite

H. Nasrallah — researcher profile on SciRah

Invite

M. A. Geist — researcher profile on SciRah

S. le Scouiller×3

Invite

S. le Scouiller — researcher profile on SciRah

D. Feuerbach×3

Invite

D. Feuerbach — researcher profile on SciRah